Metastate Metabolomics

Executive Summary

Metastate Metabolomics is a Zurich-based biotech startup that has developed Metastate Brain, a decision intelligence platform designed to help biology teams translate complex biological data and constraints into ranked experiments and actionable interventions. Founded in 2019, the company operates on a program-based commercial model, serving clients primarily in bioprocess development, discovery, and optimization. By leveraging metabolomics and other -omics data, Metastate Brain aims to reduce experimental iterations and accelerate R&D timelines, addressing a critical bottleneck in biotech and pharmaceutical development. The platform's ability to integrate multi-omics data and provide prescriptive insights positions it as a valuable tool for both academic and industrial research teams. As a private company with no disclosed funding or valuation, Metastate Metabolomics appears to be in an early growth phase, relying on its program-based revenue model. Its success hinges on expanding its client base and demonstrating ROI in real-world projects. While the company has not yet achieved high profile or publication counts, its focus on bioprocess optimization and discovery aligns with industry trends toward AI-driven decision support. With a conviction score of 65, the company shows promise but remains unproven at scale. Upcoming catalysts include potential strategic partnerships, platform expansion into new markets, or a seed/Series A funding round to fuel growth.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round70% success
• Q4 2026Strategic partnership with major pharma for bioprocess optimization50% success